Tag: Fda approval 2025

In August 2025, the U.S. Food and Drug Administration (FDA) approved Tonmya (sublingual cyclobenzaprine), the first new medication for fibromyalgia in over 15 years, offering renewed hope for millions affected by this chronic condition. This development marks a significant advancement in pharmacological treatment options, specifically targeting the non-restorative sleep that often accompanies the widespread pain of fibromyalgia.

In a significant medical breakthrough, the FDA approved Journavx (suzetrigine) in January 2025—the first new class of oral pain medication to come to market in over two decades. This groundbreaking drug directly answers the question, "What is the new painkiller that is not an op?", providing a long-awaited, non-addictive alternative for managing moderate to severe acute pain.